The iBeChange consortium is pleased to announce that the iBeChange Pilot Study officially began in December 2025, marking an important milestone in this EU-funded Horizon Europe Mission Cancer project.
The pilot study will test a digital, personalised intervention designed to support behavioural change and emotional wellbeing as part of primary cancer prevention. By combining behavioural science, psychosocial support, and digital innovation, the initiative aims to explore how tailored guidance can help individuals address modifiable lifestyle and emotional risk factors associated with cancer.
What the pilot study will explore
The iBeChange Pilot Study focuses on several core components:
- Personalised strategies for behaviour change and emotional management
- A stepped-care digital approach that combines automated support with professional input when required
- Integration of AI-driven insights to adapt recommendations over time
- Exploration of passive health monitoring through wearable technology
The study is coordinated by the Catalan Institute of Oncology, working alongside clinical and research partners across Europe, including Eurecat – Technology Centre, Eindhoven University of Technology, SporeData Inc., Università degli Studi di Palermo, and the European Institute for Innovation Through Health Data. The project is supported by the European Health and Digital Executive Agency (HaDEA).
This collaborative effort reinforces a shared commitment to developing scalable, evidence-based approaches to cancer prevention across Europe. By generating real-world evidence, the iBeCHANGE Pilot Study will help shape future interventions that are not only innovative, but also practical, ethical, and impactful across healthcare systems.
Funded by the European Union’s Horizon Europe Programme, iBeChange focuses on reducing cancer risk by addressing modifiable lifestyle and psychosocial factors, contributing to the broader goals of the EU Mission on Cancer.